Observational data on GLP-1 drugs and cancer risk remains inconclusive

Recent observational studies suggest a correlation between GLP-1 receptor agonists like Ozempic and reduced cancer incidence. However, the findings are limited by healthy-user bias and insufficient longitudinal follow-up, meaning a causal link for cancer prevention is currently unproven.